BLU-451 + carboplatin + pemetrexed

**BLU-451 + carboplatin + pemetrexed** is an investigational three-drug combination studied primarily in the context of **non-small cell lung cancer (NSCLC)**, particularly cases driven by atypical or Exon 20 insertion mutations of the **Epidermal Growth Factor Receptor (EGFR)** gene. - **BLU-451** is a covalent, CNS-penetrant, oral small molecule inhibitor designed to selectively target EGFR Exon 20 insertion mutations while sparing wild-type EGFR, thereby aiming to minimize toxicity and maximize efficacy in relevant cancer subtypes[1][3][5]. - **Carboplatin** is a platinum-based chemotherapeutic agent that promotes DNA crosslinking and induces apoptosis in rapidly dividing cells[2][4][6][8]. - **Pemetrexed** is an antifolate antineoplastic that disrupts folate-dependent metabolic processes critical for cell replication, leading to inhibition of DNA and RNA synthesis[2][4][6][8]. The combination regimen is under investigation for the treatment of advanced, EGFR-mutant NSCLC, including in patient populations with brain metastases, based on the CNS penetration of BLU-451 and the well-established efficacy of pemetrexed and carboplatin in NSCLC[3][5][6]. BLU-451 has been developed by Blueprint Medicines.

Other names

pemetrexed and carboplatin